429 related articles for article (PubMed ID: 27352377)
21. Impact of Switching From an Initial Tumor Necrosis Factor Inhibitor on Health Care Resource Utilization and Costs Among Patients With Rheumatoid Arthritis.
Baser O; Ganguli A; Roy S; Xie L; Cifaldi M
Clin Ther; 2015 Jul; 37(7):1454-65. PubMed ID: 25999184
[TBL] [Abstract][Full Text] [Related]
22. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
[TBL] [Abstract][Full Text] [Related]
23. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
[TBL] [Abstract][Full Text] [Related]
24. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
25. The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors.
Martínez-Feito A; Plasencia-Rodríguez C; Navarro-Compán V; Hernández-Breijo B; González MÁ; Monjo I; Nuño L; Nozal P; Pascual-Salcedo D; Balsa A
Clin Rheumatol; 2019 Mar; 38(3):949-954. PubMed ID: 30402698
[TBL] [Abstract][Full Text] [Related]
26. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study.
Emery P; Gottenberg JE; Rubbert-Roth A; Sarzi-Puttini P; Choquette D; Taboada VM; Barile-Fabris L; Moots RJ; Ostor A; Andrianakos A; Gemmen E; Mpofu C; Chung C; Gylvin LH; Finckh A
Ann Rheum Dis; 2015 Jun; 74(6):979-84. PubMed ID: 24442884
[TBL] [Abstract][Full Text] [Related]
27. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.
Glintborg B; Ostergaard M; Krogh NS; Andersen MD; Tarp U; Loft AG; Lindegaard HM; Holland-Fischer M; Nordin H; Jensen DV; Olsen CH; Hetland ML
Arthritis Rheum; 2013 May; 65(5):1213-23. PubMed ID: 23460467
[TBL] [Abstract][Full Text] [Related]
28. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
Jansen JP; Incerti D; Mutebi A; Peneva D; MacEwan JP; Stolshek B; Kaur P; Gharaibeh M; Strand V
J Med Econ; 2017 Jul; 20(7):703-714. PubMed ID: 28294642
[TBL] [Abstract][Full Text] [Related]
30. Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sample.
Yeaw J; Watson C; Fox KM; Schabert VF; Goodman S; Gandra SR
Adv Ther; 2014 Apr; 31(4):410-25. PubMed ID: 24604700
[TBL] [Abstract][Full Text] [Related]
31. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
[TBL] [Abstract][Full Text] [Related]
32. Cost-utility analysis of treatment options after initial tumor necrosis factor inhibitor therapy discontinuation in patients with rheumatoid arthritis.
Karpes Matusevich AR; Lai LS; Chan W; Swint JM; Cantor SB; Suarez-Almazor ME; Lopez-Olivo MA
J Manag Care Spec Pharm; 2021 Jan; 27(1):73-83. PubMed ID: 33377443
[No Abstract] [Full Text] [Related]
33. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
34. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
[TBL] [Abstract][Full Text] [Related]
35. Optimizing biological treatment in rheumatoid arthritis with the aid of therapeutic drug monitoring.
Eng GP
Dan Med J; 2016 Nov; 63(11):. PubMed ID: 27808043
[TBL] [Abstract][Full Text] [Related]
36. Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis.
Lee WJ; Briars L; Lee TA; Calip GS; Suda KJ; Schumock GT
Pharmacotherapy; 2016 Dec; 36(12):1201-1209. PubMed ID: 27779782
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of early treatment of ACPA-positive rheumatoid arthritis patients with abatacept.
Neubauer AS; Minartz C; Herrmann KH; Baerwald CGO
Clin Exp Rheumatol; 2018; 36(3):448-454. PubMed ID: 29303709
[TBL] [Abstract][Full Text] [Related]
38. Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study.
Nakayama Y; Watanabe R; Murakami K; Murata K; Tanaka M; Ito H; Yamamoto W; Ebina K; Hata K; Hiramatsu Y; Katayama M; Son Y; Amuro H; Akashi K; Onishi A; Hara R; Yamamoto K; Ohmura K; Matsuda S; Morinobu A; Hashimoto M
Rheumatol Int; 2022 Jul; 42(7):1227-1234. PubMed ID: 35266034
[TBL] [Abstract][Full Text] [Related]
39. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data.
Kievit W; Adang EM; Fransen J; Kuper HH; van de Laar MA; Jansen TL; De Gendt CM; De Rooij DJ; Brus HL; Van Oijen PC; Van Riel PC
Ann Rheum Dis; 2008 Sep; 67(9):1229-34. PubMed ID: 18174220
[TBL] [Abstract][Full Text] [Related]
40. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans.
Joyce AT; Gandra SR; Fox KM; Smith TW; Pill MW
J Med Econ; 2014 Jan; 17(1):1-10. PubMed ID: 24131136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
